What a year! Things have taken off so quickly with work, PhD and Beta Change in the last few months that I haven’t been able to keep up with my blog. So getting back into a regular blogging routine is definitely on my cards for 2018. Continue reading “2017 – recap and reflect.”
In the diabetes community, there is a push to look beyond the A1c. Traditionally, the A1c was the golden child to see how our diabetes management is going. To put it simply, the A1c is an average of all your blood glucose over the past three months, which is the lifespan of a red blood cell. The problem is that it is only an average and can be marred by a myriad of high and low numbers. Hence the push to see beyond the A1c and look a time spent in target range instead. Continue reading “HbA1c Conflict”
Late Thursday night, I received a huge shock when a friend forwarded me this press release from Johnson and Johnson. The press released announced that Animas will exit the insulin pump market, effective immediately in the States and Canada. In the meantime, Animas selected Medtronic to help phase out Animas pumps. For more details, check out their press release.
Cue sad face, disbelief, confusion and outrage across the globe. Continue reading “Goodbye Animas?”